Results 171 to 180 of about 1,203 (200)

Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases – a debate

Hoenigl, Martin, Lass-Flörl, Cornelia, Maertens, Johan, Richardson, Malcolm, Slavin, Monica, THOMPSON III, George R.   +5 more
core   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Ibrexafungerp: A new triterpenoid antifungal

American Journal of Health-System Pharmacy, 2022
Abstract Purpose The pharmacology, microbiology, pharmacokinetics, pharmacodynamics, efficacy, safety, and role of ibrexafungerp in the treatment of fungal infections are reviewed. Summary Ibrexafungerp is the first triterpenoid ...
Elias B Chahine
exaly   +3 more sources

Ibrexafungerp: First Approval

Drugs, 2021
Ibrexafungerp (BREXAFEMME®) is an orally active triterpenoid antifungal drug being developed by SCYNEXIS, Inc. for the treatment of fungal infections. The inhibition of β-1,3-D glucan synthetase by ibrexafungerp compromises the integrity of fungal cell walls.
exaly   +3 more sources

Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor

Bioorganic and Medicinal Chemistry Letters, 2021
We previously reported medicinal chemistry efforts that identified MK-5204, an orally efficacious β-1,3-glucan synthesis inhibitor derived from the natural product enfumafungin. Further extensive optimization of the C2 triazole substituent identified 4-pyridyl as the preferred replacement for the carboxamide of MK-5204, leading to improvements in ...
James M Apgar
exaly   +3 more sources

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306 [PDF]

Journal of Women's Health, 2023
Background: Ibrexafungerp is a novel antifungal treatment for acute vulvovaginal candidiasis (VVC). Using pooled data from two phase three studies (VANISH 303 and 306) in the treatment of acute VVC, this analysis sought to determine the effectiveness of ...
Oluwatosin Goje, Paul R Nyirjesy, Jack D Sobel   +2 more
exaly   +2 more sources

Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis

Annals of Pharmacotherapy, 2022
Objective To review the pharmacology, efficacy, and safety of ibrexafungerp in the management of vulvovaginal candidiasis (VVC). Data Sources Literature was sought using PubMed (1966—February 2022) and EMBASE (1973—February 2022), and clinicaltrials.gov. Search terms included ibrexafungerp, SCY-078, and VVC.
Kylie N. Barnes, Abigail M. Yancey, Alicia B. Forinash   +2 more
openaire   +2 more sources

Ibrexafungerp for the treatment of vulvovaginal candidiasis

Drugs of Today, 2022
Worldwide, effective management of vulvovaginal candidiasis (VVC) continues to serve as a major therapeutic goal with numerous unmet drug treatment challenges. After 3 decades of azole drug dominance, with few recent new antifungal agents and little progress in VVC management, the first-in-class oral triterpenoid glucan synthase inhibitor agent ...
openaire   +2 more sources